You are here: Industry Insights > Neurocrine

News List

Luvadaxistat Study Results Did Not Meet Primary Endpoint americanpharmaceuticalreview
March 08, 2021
Neurocrine Biosciences announced investigational drug luvadaxistat did not meet its primary endpoint in the Phase II INTERACT study in adults with negative symptoms of schizophrenia, as measured by the change from baseline on the PANSS NSFS at Day 84.
Neurocrine Licenses Seven Takeda Compounds in $2B Deal contractpharma
June 22, 2020
To develop and commercialize early-to-mid-stage psychiatry pipeline including assets for for schizophrenia, treatment-resistant depression and anhedonia.
Acadia, Neurocrine Could Be Next Takeovers Among Biotech Stocks firstwordpharma
March 03, 2019
Needham analyst Alan Carr identified Acadia Pharmaceuticals and Neurocrine Biosciences as potential takeover targets among biotech firms, Investor's Business Daily reported Friday.
Neurocrine's 3rd Ingrezza flop in Tourette dashes hopes for sales expansion fiercepharma
December 14, 2018
Last year, Neurocrine’s Ingrezza failed a phase 2 trial in pediatric Tourette Syndrome patients, prompting the company to use what it learned in designing a new phase 2b. But now Ingrezza has flunked that trial, too.
AbbVie, Neurocrine’s fibroid drug hits PhIII targets pharmatimes
July 24, 2018
A second late-stage study assessing AbbVie and Neurocrine’s experimental drug elagolix in women with uterine fibroids has met its primary endpoint.